You are here

Novel cancer drug stymied by rigid billing system

The problem is that there is no billing code for the US$373,000 Yescarta therapy in Medicare


A US government reimbursement system that does not fully cover the costs for Gilead Sciences Inc's complex blood cancer therapy is partly to blame for the slow uptake of the novel life-saving treatment, according to doctors who are trying to treat patients.

Only a...

Market voices on: